Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Apple

NVIDIA

In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie.

3 Innovative Growth Stocks to Buy for Next-Gen Profits

Merck has been the best performing Big Pharma stock apart from Eli Lilly over the past 3 years, 1 year, and 3 months. The company drove $59.3bn of revenues in 2022, up >20%. Guidance for FY22 is for $57.7bn - $58.9bn, reflecting falling COVID antiviral sales. Keytruda is Merck's most important asset, the cancer drug driving >40% of revenues in Q1'23. Its patent protection may expire in 2028 although Merck believes they can be extended.

Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended

AstraZeneca

Merck and AstraZeneca both appear to be well-positioned for the future. Both boast above-average dividends that look to remain viable.

Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. New data for the medicines BAVENCIO® (avelumab), ERBITUX® (cetuximab), and TEPMETKO® (tepotinib) and pipeline assets including the first-in-class investigational IAP (inhibitor of apoptosis protein) inhibitor xevinap.

Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Amazon

Alphabet

ServiceNow

BYD Company Limited

Eli Lilly

As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ: MSFT ), Amazon (NASDAQ: AMZN ) and Apple (NASDAQ: AAPL ) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time.

7 Stocks That Could Be the Next $2 Trillion-Dollar Companies

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2023 Dividend.

Merck Announces Third-Quarter 2023 Dividend

Prometheus Biosciences

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own. KSF is seeking to determine whether this consideration and the process that led to.

PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

Pfizer

Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors.

3 Undervalued Pharma Stocks to Buy for High Total Returns

Novartis

Big pharmaceutical stocks, including Novartis AG NYSE: NVS, Eli Lilly & Co. NYSE: LLY, Merck & Co. NYSE: MRK, and Novo Nordisk A/S NYSE: NVO have been outperforming the broader market recently, even as the healthcare sector as a whole lags.

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

Cardinal Health

Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy.

Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs

AbbVie

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Snap-on

Skyworks Solutions

The 4-factor dividend growth portfolio was launched on November 1st, 2022, and despite weaker performance recently, it finished ahead of the S&P 500 total return at the half-year mark. The portfolio underperformed the S&P 500 Total Return by 397 bps during the month of April.

4-Factor Dividend Growth Portfolio - Half-Year Mark

NEW YORK--(BUSINESS WIRE)-- #COVID19--Olatec Therapeutics LLC (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced it has completed the lower dose cohort and entered the second, and highest, dose cohort of the DREAM Trial, a Phase 1/2 Investigator-initiated clinical study (NCT04971499). This trial is evaluating the combination treatment of Olatec's dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma. The st.

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec's NLRP3 Inhibitor Dapansutrile and Merck's Keytruda® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck ASCO Curtain Raiser.

Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting

Merck & Co., Inc. (NYSE:MRK ) Bank of America Securities 2023 Healthcare Conference Transcript May 10, 2023 11:40 AM ET Company Participants Geoff Meacham - Analyst, Bank of America Securities Caroline Litchfield - CFO, Merck & Co., Inc. Conference Call Participants Geoff Meacham Okay. Welcome to the second day of the BofA Healthcare Conference.

Merck & Co., Inc. (MRK) Bank of America Securities 2023 Healthcare Conference Transcript

Altimmune

Amgen

Structure Therapeutics Inc

Novo Nordisk

Roche Holding AG

Viking Therapeutics

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

Weight-loss drug developers line up to tap market worth $150 billion

OPKO Health

In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Rayaldee.

OPKO Health's Future After Merck Deal: Bright Or Uncertain

JPMorgan Chase & Co

Microsoft

Earnings reports jolted Microsoft and JPMorgan shares higher, while Merck shares have been inching forward for months now. All three blue chip names have a compelling future with tangible growth prospects.

Can You Still Buy the Dow Jones' Best-Performing April Stocks?

Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued.

Should You Buy Merck Stock At $120?

Archer-Daniels-Midland Company

Ball Corp

Franklin Resources

British American Tobacco

Boston Properties

Cigna

Carlisle Companies

Coterra Energy

Chevron

EOG Resources

Enterprise Products Partners

Johnson & Johnson

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying and are offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Conservative And Cheap Dividend Stocks To Invest In - May 2023

News for Merck Stock (MRK)